Is evolving APAC healthcare ecosystem addressing current regulatory bottlenecks?
With the innovation boom in Asia and many early-stage assets emerging, the time is ripe for Asian economies to establish cross-border business relationships by systematically tapping potential markets for successful market penetration. Regulatory compliance and patient protection are simultaneously enhanced by increasing investments in technology to meet quality and efficacy which are paramount in the pharma/biopharma and clinical trial space. Yet, with the rapidly changing regulatory expectations, certain regions in APAC experience regulatory inertia which can hinder development and bilateral trade. Despite the challenges, Asian economies are adopting evolving policies and regulations supporting operations. However, can regulatory reforms bring down the cost and time required to bring a product to market? Edwin Ng, Senior Vice President, General Manager (Asia-Pacific), Life Science at Dassault Systèmes shares more insights with Biospectrum Asia.